Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder
Status:
Not yet recruiting
Trial end date:
2023-01-21
Target enrollment:
Participant gender:
Summary
This research study evaluates the effects of anFDA-approved medication NAC in individuals
with Bipolar Disorder. Participants in the study will will be assigned to two medication
conditions and will take both NAC and a matched placebo. The order in which they take each
medication will be random. Study medication will be taken for 14 days. There will be 5 study
visits, with 2 MRI brain imaging scans completed. Questionnaires and clinical interview
measures will be completed at study visits along with consistent assessment of potential side
effects from study medication.
Phase:
Phase 2
Details
Lead Sponsor:
Medical University of South Carolina
Collaborator:
Milken Institute Center for Strategic Philanthropy